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The mechanisms that promote excitatory synapse
formation and maturation have been extensively
studied. However, the molecular events that limit
excitatory synapse development so that synapses
form at the right time and place and in the correct
numbers are less well understood. We have identi-
fied a RhoA guanine nucleotide exchange factor,
Ephexin5, which negatively regulates excitatory
synapse development until EphrinB binding to the
EphB receptor tyrosine kinase triggers Ephexin5
phosphorylation, ubiquitination, and degradation.
The degradation of Ephexin5 promotes EphB-
dependent excitatory synapse development and is
mediated byUbe3A, a ubiquitin ligase that ismutated
in the human cognitive disorder Angelman syndrome
and duplicated in some forms of Autism Spectrum
Disorders (ASDs). These findings suggest that
aberrant EphB/Ephexin5 signaling during the devel-
opment of synapses may contribute to the abnormal
cognitive function that occurs in Angelman syn-
drome and, possibly, ASDs.
INTRODUCTION
A crucial early step in the formation of excitatory synapses is the
physical interaction between the developing presynaptic
specialization and the postsynaptic dendrite (Jontes et al.,
2000; Ziv and Smith, 1996). This step in excitatory synapse
development is thought to be mediated by cell surface mem-
brane proteins expressed by the developing axon and dendrite
and appears to be independent of the release of the excitatory
neurotransmitter glutamate (reviewed in Dalva et al., 2007).
Several recent studies have revealed an important role for Ephrin
cell surface-associated ligands and Eph receptor tyrosine
kinases in this early cell-cell contact phase that is critical for
excitatory synapse formation (Dalva et al., 2000; Ethell et al.,442 Cell 143, 442–455, October 29, 2010 ª2010 Elsevier Inc.2001; Henkemeyer et al., 2003; Kayser et al., 2006; Kayser
et al., 2008; Lai and Ip, 2009; Murai et al., 2003). Ephs can be
divided into two classes, EphA and EphB, based on their ability
to bind the ligands EphrinA and EphrinB, respectively (reviewed
in Flanagan and Vanderhaeghen, 1998). EphBs are expressed
postsynaptically on the surface of developing dendrites, while
their cognate ligands, the EphrinBs, are expressed on both the
developing axon and dendrite (Grunwald et al., 2004; Grunwald
et al., 2001; Lim et al., 2008). When an EphrinB encounters an
EphB on the developing dendrite, EphB becomes autophos-
phorylated, thus increasing its catalytic kinase activity (reviewed
in Flanagan and Vanderhaeghen, 1998). This leads to a cascade
of signaling events including the activation of guanine nucleotide
exchange factors (GEFs) Tiam, Kalirin, and Intersectin, culmi-
nating in actin cytoskeleton remodeling that is critical for excit-
atory synapse development (reviewed in Klein, 2009). Consistent
with a role for EphBs in excitatory synapse development, EphB1/
EphB2/EphB3 triple knockout mice have fewer mature excit-
atory synapses in vivo in the cortex, and hippocampus (Henke-
meyer et al., 2003; Kayser et al., 2006). In addition, the disruption
of EphB function postsynaptically in dissociated hippocampal
neurons leads to defects in spinemorphogenesis and a decrease
in excitatory synapse number (Ethell et al., 2001; Kayser et al.,
2006). Conversely, activation of EphBs in hippocampal neurons
leads to an increase in the number of dendritic spines and
functional excitatory synapses (Henkemeyer et al., 2003; Penzes
et al., 2003).These findings indicate that EphBs are positive
regulators of excitatory synapse development.
While there has been considerable progress in characterizing
the mechanisms by which EphBs promote excitatory synapse
development, it is not known if there are EphB-associated
factors that restrict the timing and extent of excitatory synapse
development.We hypothesized that neuronsmight have evolved
mechanisms which act as checkpoints to restrict EphB-medi-
ated synapse formation, and that the release from such synapse
formation checkpoints might be required if synapses are to form
at the correct time and place and in appropriate numbers.
We considered the possibility that likely candidates tomediate
the EphB-dependent restriction of excitatory synapse formation
might be regulators of RhoA, a small G protein that functions to
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Figure 1. Ephexin5 Interacts with EphB2
(A) E5 and EphB2 are expressed in the CA1 region and dentate gyrus (DG) of
the hippocampus at P12. Adjacent 14 mm mouse brain sections were stained
for E5 or EphB2 using digoxigenin-labeled RNA probes to the antisense strand
or sense strand as a control (top). Lower panels show nuclear staining with
DAPI.
(B) Immunoprecipitation with a-Flag from 293 cell lysates previously trans-
fected with various combinations of overexpressing plasmids containing
E1-Myc, E5-Myc, Flag-EphB2, and/or Flag-EphA4, followed by immunoblot-
ting with a-Myc or a-Flag. Input protein levels are shown (bottom).
(C) Immunoprecipitation of mouse cortical lysates with IgG or a-C-E5, followed
by immunoblotting with a-EphB2 or a-N-E5 (left). Input protein levels are
shown (right).
(D) Immunoprecipitation of WT or E5/ mouse cortical culture lysates with
a-C-E5 followed by immunoblotting with a-EphB2. Input EphB2 levels are
shown (bottom).
(E) Dissociated rat hippocampal neurons were stained using a-N-E5 (Blue) and
a-EphB2 (Red). A representative image of overlapped EphB2 and E5 is shown
(left). White rectangle outlines magnified dendritic region (right) showing
examples of EphB2/E5 colocalization (arrows). In three independent experi-
ments, quantification of overlapped EphB2/E5 puncta was determined at
DIV2, DIV4 and DIV8 and is represented as percent of EphB2 overlapped
with E5 (right). Error bars ± SEM; *p < 0.05, nonsignificant (n.s.).
See also Figure S1.antagonize the effects of Rac (Tashiro et al., 2000). In previous
studies we identified a RhoAGEF, Ephexin1 (E1), which interacts
with EphA4 (Fu et al., 2007; Sahin et al., 2005; Shamah et al.,
2001). E1 is phosphorylated by EphA4 and is required for the
EphrinA-dependent retraction of axonal growth cones and
dendritic spines (Fu et al., 2007; Sahin et al., 2005). While E1
does not appear to interact with EphB, E1 is amember of a family
of five closely related GEFs. Of these GEFs, Ephexin5 (E5) (in
addition to E1) is highly expressed in the nervous system. There-
fore, we hypothesized that E5 might function to restrict the
EphB-dependent development of excitatory synapses by
activating RhoA.
In this study we report that EphB interacts with E5, that E5
suppresses excitatory synapse development by activating
RhoA, and that this suppression is relieved by EphrinB activation
of EphB during synapse development. Upon binding EphrinB,
EphB catalyzes the tyrosine phosphorylation of E5 which trig-
gers E5 degradation. We identify Ube3A as the ubiquitin ligase
that mediates E5 degradation, thus allowing synapse formation
to proceed. As Ube3A is mutated in Angelman syndrome and
duplicated in some forms of Autism Spectrum Disorders
(ASDs), these findings suggest a possible mechanism by which
themutation of Ube3Amight lead to cognitive dysfunction (Jiang
et al., 1998; Kishino et al., 1997). Specifically, we provide
evidence that in the absence of Ube3A, the level of E5 is elevated
and propose that this may lead to the enhanced suppression of
EphB-mediated excitatory synapse formation, thereby contrib-
uting to Angelman syndrome.
RESULTS
Ephexin5 Interacts with EphB2
To identify mechanisms that restrict the ability of EphBs to
promote an increase in excitatory synapse number, we searched
for guanine nucleotide exchange factors (GEFs) that specifically
activate RhoA signaling, are expressed in the same population of
neurons that express EphB, are expressed at the same time
during development as EphB, and interact with EphB. Struc-
ture-function studies of GEFs identified amino acid residues in
the activation domain of Rho family GEFs that specifically iden-
tify the GEFs as activators of RhoA rather than Rac or Cdc42.
Applying this criterion, fourteen GEFs were identified that specif-
ically activate RhoA (Rossman et al., 2005). Of these GEFs we
found by in situ hybridization that E5 has a similar expression
pattern to EphB in the hippocampus (Figure 1A). These findings
raised the possibility that E5might mediate the effect of EphB on
developing synapses.
We asked if E5 interacts physically with EphB. We transfected
HEK293T (293) cells with plasmids encodingMyc-tagged E5, E1,
or a vector control together with Flag-tagged EphB2 or EphA4
and asked if these proteins coimmunoprecipitate. Extracts
were prepared from the transfected 293 cells and EphA4 or
EphB2 immunoprecipitated with Flag antibodies. The immuno-
precipitates were subjected to SDS polyacrylamide gel electro-
phoresis (SDS-PAGE) and blotted with anti-Myc antibody
(a-Myc). We found that E5 coimmunoprecipitates with EphB2
but not with EphA4 (Figure 1B). The relatively weak E5 interaction
with EphA4 is consistent with published experiments (OgitaCell 143, 442–455, October 29, 2010 ª2010 Elsevier Inc. 443
et al., 2003). By contrast, E1 is coimmunoprecipitated by EphA4
but not EphB2 (Shamah et al., 2001). These findings suggest that
E5 interacts preferentially with EphB2.
To extend this analysis we investigated whether EphB2
interacts with E5 in neurons. Neurons from embryonic day 16
(E16) mouse brains were lysed in RIPA buffer and the lysates
incubated with affinity purified anti-C-terminal E5 (a-C-E5) or
control (IgG) antibodies. The immunoprecipitates were then
resolved by SDS-PAGE and immunoblotted with affinity purified
anti-N-terminal E5 (a-N-E5) or EphB2 (a-EphB2) antibodies
(Figure 1C). This analysis revealed that endogenous, neuronal
EphB2 is immunoprecipitated by a-C-E5 but not IgG. Moreover,
using lysates from cortical cultures of wild-type or E5 knockout
mice (E5/, see Figure S1 available online), we find that
a-C-E5 immunoprecipitates EphB2 only from lysates when E5
is present (Figure 1D). Taken together, these findings suggest
that EphB interacts with Ephexin5 in neurons.
As an independent means of assessing if EphB and E5 interact
with one another, we used immunofluorescence microscopy to
determine if these two proteins colocalize in neurons. Cultured
mouse hippocampal neurons were transfected with a plasmid
expressing green fluorescent protein (GFP). The GFP-express-
ing neurons were imaged and quantified for the colocalization
of EphB2 and E5 puncta by staining with a-C-E5 and a-EphB2.
This analysis revealed that EphB2 and E5 colocalize along
dendrites (Figure 1E). We find that 40% of EphB staining over-
laps with a-C-E5 staining early during the development of
excitatory synapses. After eight days in vitro (DIV) the overlap
of EphB with E5 within neuronal dendrites decreases to below
the level that would be detected by random chance. This change
suggests that EphB interacts with E5 early during development
but that these two proteinsmay not interact later in development.
Ephexin5 Is a Guanine Nucleotide Exchange Factor
that Activates RhoA
To determine if E5 activates RhoA, we transfected 293 cells with
a control plasmid or a plasmid that drives the expression of
Myc-tagged mouse E5. We prepared extracts from the trans-
fected cells and incubated the extracts with aGST-fusion protein
that includes the Rhotekin-Binding Domain (GST-RBD), a protein
domain that selectively interacts with active (GTP-bound) but not
inactive (GDP-bound) RhoA. Following SDS-PAGE of the
proteins in the extract that bind to GST-RBD, RhoA binding to
GST-RBD was measured by immunoblotting with a-RhoA anti-
bodies.We found that cells expressing E5 exhibited higher levels
of activated RhoA compared to cells transfected with a control
plasmid, indicating that E5 activates RhoA (Figure 2A).
When a similar series of experiments were performed using
a GST-fusion Pak-Binding Domain (GST-PBD) which specifically
interacts with active forms of two other Rho GTPases, Rac1 and
Cdc42, we found that E5 does not induce the binding of
GST-PBD to Rac1 or Cdc42. In contrast, E1-expressing cells
displayed enhanced binding of Rac1 and Cdc42 to GST-PBD.
We conclude that E5 activates RhoA but not Rac1 or Cdc42
(Figure S2A).
To determine whether E5 activation of RhoA requires the GEF
activity of E5, we generated a mutant form of E5 in which its GEF
activity is impaired. To identify the residues required for444 Cell 143, 442–455, October 29, 2010 ª2010 Elsevier Inc.Ephexin5 guanine nucleotide exchange activity we compared
its Dbl-homology (DH) domain to the DH domain of other
RhoA-specific GEFs (Snyder et al., 2002). We identified within
the a5 helix of E5’s DH domain three amino acids that are
conserved in other GEFs that, like E5, activate RhoA but not
Rac1 and Cdc42 (Figure S2B). To generate a form of E5 pre-
dicted to be inactive as a GEF, we mutated these three
conserved amino acids (L562, Q566, and R567) to alanine
(E5-LQR). Using the GST-RBD pull-down assay we found that
although E5-WT and E5-LQR are expressed at similar levels,
the E5-LQR mutant is significantly impaired relative to WT in its
ability to activate RhoA (Figure 2B). As a control, we mutated
other conserved residues within the a5 DH region to alanine
(Q547, S548, R555, and L556). When we tested this mutant we
observed no defect in RhoA activation, suggesting that the
E5-LQR mutation specifically disrupts the GEF activity of E5
and that the inability of the LQR mutant to activate RhoA is not
a general consequence of disrupting the a5 region of Ephexin5
(Figure S2C). Taken together, these findings indicate that E5
requires an intact conserved GEF domain to promote RhoA
activity in 293 cells, suggesting that E5 functions as a RhoAGEF.
We next asked if E5 expression affects RhoA activity in the
brain. We lysed P3 whole brains from wild-type or E5/ mice
and performed a GST-RBD pull-down assay. This analysis re-
vealed a significant decrease in RhoA activation in brain extracts
from E5/mice compared towild-typemice, suggesting that E5
is required to maintain wild-type levels of RhoA activity in the
brain (Figure 2C).
Ephexin5 Negatively Regulates Excitatory
Synapse Number
Our findings indicate that E5 interacts with EphB, a key regulator
of excitatory synapse development. Thus, we asked whether E5
plays a role in the development of excitatory synapses. We
generated two short hairpin RNA constructs that each knocks
down E5 protein levels when expressed in 293 cells or cultured
hippocampal neurons (Figures S3A–S3B). These shRNAs were
introduced into cultured hippocampal neurons together with a
plasmid that drives expression of green fluorescent protein
(GFP) to allow detection of the transfected cells. We found by
staining with a-N-E5 antibodies that the E5 shRNAs (E5-shRNA),
but not scrambled hairpin control shRNAs (ctrl-shRNA), effi-
ciently knocked down E5 expression in the transfected neurons
(Figure S3C).
By staining with antibodies that recognize pre- and postsyn-
aptic proteins or by visualizing dendritic spines in GFP trans-
fected neurons we observed a significant increase in the number
of excitatory synapses and dendritic spines that are present on
the E5-shRNA-expressing neurons compared to neurons ex-
pressing ctrl-shRNAs (Figures 3A and 3B). By contrast, we failed
to detect a significant change in dendritic spine length or width
under these conditions (Figure S3D). These findings suggest
that E5 functions to restrict spine/excitatory synapse number
but has no significant effect on spine morphology. Consistent
with these conclusions, we found that overexpression of E5 in
hippocampal neurons leads to a decrease in the number of excit-
atory synapses that are present on the E5-overexpressing
neurons (Figure 3C). This ability of E5 to negatively regulate
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Figure 2. Ephexin5 Is a GEF that Activates RhoA
(A) Lysates from 293 cells transfected with empty vector (Ctrl) or E5-Myc
overexpressing vector (WT) were assayed for endogenous RhoA activity using
the RBD pull-down assay and analyzed by immunoblotting with an antibody to
RhoA (top). GTPgS lane is a positive control for inducing RhoA activity.
Increased endogenous RhoA activity is demonstrated by presence of
a-RhoA signal in RBD pull-down lanes. Input protein levels and a-Actin loading
control are shown (bottom).
(B) Lysates from 293 cells transfected with empty vector (Ctrl), E5-Myc (WT) or
LQRmutant of E5-Myc (LQR) were assessed for RhoA activity as measured by
RBD assay described in (A). Input protein levels and a-Actin loading control are
shown (bottom).
(C) Presence of E5 is critical for wild-type levels of endogenous RhoA signaling
in vivo. P3 mouse whole brain lysates from WT or E5/ (KO) littermates were
subjected to RBD pull-down assays as described in (A). A representative
immunoblot is shown (top). From three experiments, blinded to condition,
the quantification of a-RhoA signal in the RBD pull-down assay was normal-
ized to input RhoA signal (bottom). Error bars indicate ± SEM; *p < 0.05.
See also Figure S2.excitatory synapse number requires its RhoA GEF activity, as
overexpression of E5-LQR had no effect on synapse number
(Figure 3D).
To assess the effect of reducing E5 levels on the functional
properties of excitatory synapses, we recorded miniature excit-
atory postsynaptic currents (mEPSCs) from cultured hippo-
campal neurons transfected with E5-shRNA or ctrl-shRNA. We
observed an increase in the frequency and amplitude ofmEPSCs
on neurons expressing E5-shRNA compared to ctrl-shRNA
(Figure 3E). This suggests that E5 acts postsynaptically to restrict
excitatory synapse function. The increase in mEPSC frequency
could be due to an increase in presynaptic vesicle release onto
the transfected neuron or an increase in the number of excitatory
synapses that are present on the transfected neuron. We favor
the latter possibility since our transfection protocol selectively
reduces E5 levels postsynaptically and also because an increase
in synapse number would bemost consistent with the increase in
costaining of pre- and postsynaptic markers that we observe
when the level of E5 is reduced. The possibility that E5 functions
postsynaptically is further supported by immunofluorescence
staining experiments demonstrating that E5 is enriched in
dendrites relative to axons (Figure S1F).
As an independentmeans of assessing the importance of E5 in
the control of excitatory synapse number, we cultured hippo-
campal neurons from E5/ mice or their wild-type littermates
for 10 days in vitro and then, following transfection of a GFP-ex-
pressing plasmid into these neurons, quantified the number of
excitatory synapses present on the transfected neuron at
DIV14. We observed a three-fold increase in the number of
synapses that are present on E5/ neurons compared to E5+/
neurons (Figure 4A). Taken together with the E5-shRNA knock-
down and E5 overexpression analyses, these findings suggest
that E5 acts postsynaptically to reduce excitatory synapse
number.
We next asked if E5 regulates synapse number in the context
of an intact developing neuronal circuit using conditional E5
(E5fl/fl) animals (see Figure S1). Upon introduction of Cre recom-
binase into E5fl/fl cells, exons 4–8 of the E5 gene are excised
resulting in a cell that no longer produces E5 protein (data notCell 143, 442–455, October 29, 2010 ª2010 Elsevier Inc. 445
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Figure 3. Ephexin5 Negatively Regulates Excitatory Synapse Number
(A) 10 ng of E5-shRNA or Ctrl-shRNAwas cotransfected with GFP into rat hippocampal neurons at DIV14. At DIV18 dendritic spines were measured as described
in methods. Representative image illustrates dendritic spines. N indicates number of neurons assessed. Error bars indicate ± SEM; **p < 0.01, ANOVA.
(B) 10 ng or 20 ng of two different E5-shRNA or Ctrl-shRNA constructs were cotransfected with GFP into rat hippocampal neurons at DIV10. At DIV14 excitatory
synapses were measured as described in methods. Representative image illustrates quantified synapse puncta (white). Error bars indicate ± SEM; **p < 0.01,
***p < 0.005, ANOVA.
(C) DIV10 rat hippocampal neurons were cotransfected with GFP and increasing concentrations of E5-Myc or control plasmid. At DIV 14 excitatory synapses
(gray bars) and exogenous E5 expression (blue bars) were measured as described in methods. Representative image illustrates localization of E5-Myc on
transfected neuron (red). Error bars indicate ± SEM; **p < 0.01, ANOVA.
(D) Neurons were transfected with E5-Myc (E5-WT) or E5-LQR-Myc (E5-LQR) and quantified as in (C). Error bars indicate ± SEM; **p < 0.01, ANOVA.
(E) Quantification ofmEPSC inter-event interval and amplitude from hippocampal neurons transfected as in (B) with 20 ng of shRNA. Cumulative distribution plots,
bar graphs and representative traces are shown. Error bars represent the standard deviation of the mean, ***p < 0.005, *p < 0.05.
See also Figure S3 and Figure S1.
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shown). Organotypic slices were prepared from the hippo-
campus of the E5fl/fl mice or their wild-type littermates. Using
the biolistic transfection method, a plasmid expressing Cre re-
combinase was introduced into a low percentage of neurons in
the slices. We found that introduction of a Cre-expressing
plasmid into E5fl/fl neurons in the hippocampal slice led to a
significant increase in the density of dendritic spines present
on the Cre-expressing neurons relative to wild-type hippo-
campal slices transfected with Cre (Figure 4B). The length and
width of dendritic spines analyzed in these experiments showed
no significant difference between wild-type and E5/ neurons
(Figure S4). Thus, elimination of E5 expression in neurons in
the context of an intact neuronal circuit leads to an increase in
the number of dendritic spines.
To assess the role of E5 in hippocampal circuit development
in vivo, we performed acute slice physiology experiments in
the CA1 region of the hippocampus from wild-type or E5/
mice. We find that relative to wild-type neurons, in E5/ CA1
pyramidal neurons there are more frequent excitatory events
that have larger amplitude (Figure 4C). A possible explanation
for these findings is that when E5 function is disrupted during
in vivo development more excitatory synapses form resulting in
more excitatory postsynaptic events. To test this possibility,
we used array tomography to quantify the number of excitatory
synapses that form in the CA1 stratum radiatum of wild-type
and E5/ mice. We observed a 2-fold increase in the number
of excitatory synapses within the CA1 region of the E5/ hippo-
campus compared to wild-type mice (Figure 4D). Specifically,
the number of juxtaposed synapsin and PSD-95 puncta was
quantified and considered a measurement of the number of
excitatory synapses that formwithin the CA1 region of the hippo-
campus in vivo. This analysis revealed a significant increase in
the number of PSD-95 puncta but no change in the number of
synapsin puncta density (Figure 4D). This suggests that the
increase in excitatory synapse number in the stratum radiatum
of E5/mice is likely due to the absence of E5 postsynaptically
and that when E5 is present within dendrites it functions to nega-
tively regulate synapse number in vivo. On the basis of these
results, we conclude that a key function of E5 is to restrict excit-
atory synapse number during the development of neuronal
circuits.
Ephexin5 Restricts EphB2 Control of Excitatory
Synapse Formation
We next considered the possibility that the ability of E5 to
restrict excitatory synapse number might be controlled by
EphB2 signaling. To test this idea, we asked whether reducing
EphB2 signaling eliminates the increase in excitatory synapse
number detected when E5 levels are knocked down by expres-
sion of E5-shRNA. To block EphB2 activation, we introduced
into neurons a kinase dead version of EphB2 (EphB2-KD) which
has been previously shown to block EphB2 signaling (Dalva
et al., 2000). As described above, expression of E5-shRNA in
neurons leads to a significant increase in the number of
synapses that are present on the E5-shRNA-expressing neuron.
However, this increase was reversed if the E5-shRNA was
cotransfected with a plasmid that drives expression of EphB2-
KD, but was not affected by cotransfection of a control plasmid(Figure 4E). These findings suggest that the increase in excit-
atory synapse number that occurs when E5 levels are reduced
requires EphB signaling. Consistent with this conclusion, we
find that if we overexpress wild-type EphB2 in neurons more
synapses are present on the EphB-expressing neuron.
However, this effect is reduced if E5 is overexpressed in
neurons together with EphB (Figure 4F). It is possible that the
ability of overexpressed E5 to suppress the synapse-promoting
effect of EphB2 reflects independent actions of these two
signaling molecules. However, given that EphB2 and E5 interact
with one another in neurons, the most likely interpretation of
these results is that E5 functions directly to restrict the
synapse-promoting effects of EphB2. If this were the case, we
would predict that for EphB2 to positively regulate excitatory
synapse development it would be necessary to inactivate and/
or degrade E5.EphB Mediates Phosphorylation of Ephexin5
at Tyrosine-361
We considered the possibility that since EphB2 is a tyrosine
kinase it might inhibit the GEF activity or expression of the E5
protein by catalyzing the tyrosine phosphorylation of E5. In sup-
port of this possibility, stimulation of dissociated mouse hippo-
campal neurons with EphrinB1 (EB1) for 15 min led to an
increase in the level of E5 tyrosine phosphorylation as detected
by probing immunoprecipitated E5 with the pan-anti-phospho-
tyrosine antibody, 4G10 (Figure 5A).
We have previously shown that EphrinA1 stimulation of
cultured neurons leads to the tyrosine phosphorylation of E1 at
tyrosine 87 (Sahin et al., 2005). On the basis of this finding we
hypothesized that exposure of neurons to EB1 might promote
the phosphorylation of the analogous tyrosine residue (Y361)
on E5 (Figure 5B) and that phosphorylation at this site might
lead to E5 inactivation. To address this possibility, we overex-
pressed EphB2 in 293 cells together with wild-type E5 or
amutant formof E5 inwhichY361 is converted to a phenylalanine
(E5-Y361F). Lysates were prepared from the transfected cells
and after SDS-PAGEwere immunoblottedwith 4G10 (Figure 5C).
We found that in the presence of EphB2, E5-WT, but not
E5-Y361F, becomes tyrosine phosphorylated. These findings
suggest that EphB2 catalyzes the tyrosine phosphorylation of
E5 primarily at Y361.
To show definitively that E5 Y361 is tyrosine phosphorylated,
we generated an E5 phospho-Y361 antibody (a-pY361). To
demonstrate that this antibody specifically recognizes the
Y361-phosphorylated form of E5, we immunoblotted cell lysates
prepared from 293 cells that express EphB2 and either E5-WT or
E5-Y361F with a-pY361. This analysis demonstrated that
a-pY361 bind to wild-type E5 but not E5-Y361F (Figure 5C).
Furthermore, using a-pY361 we found that when wild-type
EphB2, but not a kinase dead or cytoplasmic truncated version
of EphB2, is expressed in 293 cells together with E5, E5
becomes phosphorylated at Y361 (Figure S5A). In contrast,
when EphA4 or EphA2 were expressed in 293 cells we detected
little to no phosphorylation of E5 at Y361 (Figure S5B). These
findings suggest that EphB2, but not EphAs, promote E5 Y361
phosphorylation (pY361).Cell 143, 442–455, October 29, 2010 ª2010 Elsevier Inc. 447
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Figure 4. Ephexin5 Restricts EphB2 Control of Excitatory Synapse Formation
(A) E16 hippocampi from E5+/ or E5/ mice were dissected and dissociated for culture. At DIV10 dissociated neurons were transfected with GFP. At DIV14
neurons were fixed, stained, and excitatory synapses were measured as described in methods. Error bars indicate ± SEM; ***p < 0.005, ANOVA.
(B) Organotypic slices from WT or E5fl/fl mice were biolistically transfected with Cre-recombinase (Cre) and dendritic spines were quantified as described in
methods. Representative images are shown (left). Error bars indicate ± SEM; ***p < 0.005, KS test.
(C) Quantification of mEPSC inter-event interval and amplitude from acute hippocampal brain slices prepared from P12-P14WT or E5/mice. Error bars repre-
sent the standard deviation of the mean; ***p < 0.005, *p < 0.05.
(D) Hippocampi from three independent littermate pairs consisting of P12 WT and E5/ mice were prepared as described in methods for quantification of
synapses, Synapsin1 and PSD-95 using array tomography. Error bars ± SEM; *p < 0.05, Mann-Whitney U-Test.
(E) Increase in excitatory synapse number following loss of E5 requires EphB2 signaling. At DIV10, control plasmid () or EphB2KD plasmid (+) were coexpressed
in dissociated mouse hippocampal neurons with GFP and either Ctrl-shRNA or E5-shRNA. At DIV14 excitatory synapses were measured as described in
methods. Error bars indicate ± SEM; **p < 0.01, ***p < 0.005, ANOVA.
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We also found by immunoblotting with a-pY361 that E5
is phosphorylated at Y361 in the hippocampus of wild-type but
not E5/mice (Figure S5C), and that EB1 stimulation of cultured
hippocampal neurons leads to E5 Y361 phosphorylation (Fig-
ure 5D). By immunofluorescence microscopy we detect
punctate a-pY361 staining along the dendrites of EB1-treated
wild-type neurons, but less staining in untreated neurons (Fig-
ure 5E). This result suggests that E5 becomes newly phosphor-
ylated at Y361 upon exposure of hippocampal neurons to EB1.
EphB2-Mediated Degradation of Ephexin5
Is Kinase- and Proteasome Dependent
We asked if EB1 stimulation of E5 Y361 phosphorylation leads
to a change in E5 activity or expression. To investigate this
possibility we asked if EphB suppresses E5-dependent RhoA
activation in a phosphorylation-dependent manner. We trans-
fected 293 cells with E5 in the presence or absence of EphB2
and measured RhoA activity using the RBD pull-down assay
(Figure 5F). We found that E5-dependent RhoA activation was
reduced in 293 cells expressing EphB2 and E5 compared to cells
expressing E5 alone. These findings are consistent with the
possibility that EphB2-mediated tyrosine phosphorylation of E5
either leads to a suppression of E5’s ability to activate RhoA,
or alternatively might trigger a decrease in E5 protein expression
resulting in a decrease in RhoA activation. We found this latter
possibility to be the case (Figure 5F, E5 loading control). Further-
more, when we compared lysates from the brains of wild-type or
EphB2/mice, we observed that E5 phosphorylation at Y361 is
decreased while the levels of E5 expression are increased in the
lysates from EphB2/mice (Figure 5G). These data suggest that
EphB2 functions to phosphorylate and degrade E5.
Consistent with the idea that E5 expression is destabilized in
the presence of EphB, we observed that in the dendrites of
cultured hippocampal neurons overexpressing EphB2, endoge-
nous E5 expression levels are reduced compared to control
transfected neurons or neurons transfected with a kinase dead
version of EphB2 (Figures S6A and S6B). When neurons were
exposed to EB1 compared to EA1 for 60min, we found by immu-
noblotting of neuronal extracts, or immunofluorescence staining
with a-N-E5, that exposure to EB1 leads to a decrease in E5
expression (Figure 6A). The lack of complete loss of E5 expres-
sion by Western blot may be due to the fact that EB1 stimulation
leads to dendritic and not somatic loss of E5 expression. More-
over, immunofluorescence staining revealed a loss of E5 puncta
specifically within the dendrites of EB1-stimulated neurons,
consistent with the possibility that EB1/EphB-mediated degra-
dation of E5 relieves an inhibitory constraint that suppresses
excitatory synapse formation on dendrites (Figure 6A). In support
of this idea, we find by immunoblotting of extracts from mouse
hippocampi that endogenous E5 protein levels are highest at
postnatal day 3 prior to the time of maximal synapse formation
and then decrease as synapse formation peaks in the postnatal
period (Figure S6C). Northern blotting revealed that this(F) E5 can suppress an EphB2-mediated increase in excitatory synapse numbe
pressed in dissociated mouse hippocampal neurons with GFP and either control (
as described in methods. Error bars indicate ± SEM; **p < 0.01, ***p < 0.005, AN
See also Figure S4 and Figure S1.decrease in E5 protein is not due to a change in the level of E5
mRNA expression (Figure S6C). Given that E5 protein levels
decrease dramatically during the time period P7-P21 when
synapse formation is maximal, these findings suggest that E5
may need to be degraded prior to synapse formation.
We asked whether EphB-mediated degradation of E5 could be
reconstituted in heterologous cells. When EphB and Myc-tagged
E5 were coexpressed in 293 cells we observed a significant
decrease in E5 protein expression in the presence of EphB2
(Figure 6B). The presence of EphB2 had no effect on the level of
expression of a related GEF, E1 (Figure 6B). We asked whether
EphB-mediated degradation of E5 depends upon Y361 phos-
phorylation. We found that in 293 cells overexpressing Myc-
tagged E5, the coexpression of EphB2, but not EphB2-KD,
resulted in a significant decrease in E5 levels (Figure 6C). This
suggests that EphB tyrosine kinase activity is required for E5
degradation. The EphB-mediated reduction in E5 levels is depen-
dent onY361phosphorylation, asEphB2expressionhadnoeffect
on the level ofE5Y361Fexpression (Figure 6D). This suggests that
the phosphorylation of E5 at Y361 triggers E5 degradation.
We considered the possibility that the Y361 phosphorylation-
dependent decrease in E5 protein levels might be due to
EphB-dependent stimulation of E5 proteasomal degradation.
Consistent with this possibility we found that addition of the
proteasome inhibitor lactacystin to 293 cells leads to a reversal
of the EphB-dependent decrease in E5 protein levels, as
measured by an increase in total ubiquitinated E5 (Figure S6D).
In addition, in neuronal cultures the EB1 induced decrease in
E5 protein expression is blocked if the proteasome inhibitor lac-
tacystin is added prior to EB1 addition (Figure 6E). Notably, in the
presence of lactacystin, E5 is ubiquitinated, further supporting
the idea that E5 is degraded by the proteasome.
To test whether E5 is ubiquitinated in the brain, we incubated
wild-type or E5/brain lysates with a-C-E5 and after immuno-
precipitation and SDS-PAGE, probed with a-ubiquitin anti-
bodies. This analysis detected the presence of ubiquitinated
species in a-C-E5 immunoprecipitates prepared from wild-type
but not E5/ brain lysates (Figure 6F). These findings indicate
that E5 is ubiquitinated in the brain.
EphB2-Mediated Degradation of Ephexin5
Requires Ube3A
During proteasome-dependent degradation of proteins, speci-
ficity is conferred by E3 ligases or E2 conjugating enzymes
that recognize the substrate to be degraded. The E3 ligase binds
to the substrate and catalyzes the addition of polyubiquitin side
chains to the substrate thereby promoting degradation via the
proteasome (Hershko and Ciechanover, 1998). We considered
several E3 ligases that have recently been implicated in synapse
development as candidates that catalyze E5 degradation. One of
these E3 ligases, Cbl-b, has previously been implicated in the
degradation of EphAs and EphBs (Fasen et al., 2008; Sharfe
et al., 2003). A second E3 ligase, Ube3A, has been shown tor. At DIV10, control plasmid () or EphB2-expressing plasmid (+) were coex-
Ctrl) plasmid or E5-Myc plasmid. At DIV14 excitatory synapses were measured
OVA.
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Figure 5. EphB2 Mediates Phosphorylation of Ephexin5 at Tyrosine-361
(A) Dissociated mouse hippocampal neurons were stimulated with either a -Fc IgG (Ctrl) or preclustered Fc-EB1 for 15 min. Neuronal lysates were immunopre-
cipitated with a-N-E5, followed by immunoblotting for panphosphotyrosine (a-pTyr) or E5 with a-N-E5. EB1 stimulation was determined by immunoblotting
neuronal lysates for phospho-Eph (pEph). Input protein levels and a-Actin loading control are shown (bottom).
(B) E5-Y361 is a conserved residue with E1-Y87 (Sahin et al., 2005).
(C) Immunoprecipitation with a-Myc from 293 cell lysates previously transfected with various combinations of overexpressing plasmids containing E5-Myc, E5
(Y361F)-Myc and/or EphB2-Flag, followed by immunoblotting with a-pTyr, a-Myc, a-pY361 or a-Flag. Input EphB2 levels are shown (bottom).
(D) Neurons were treated and lysates prepared as in panel (A) followed by immunoblotting with a-pY361 or a-N-E5. Representative immunoblot with input phos-
pho-Eph (pEph) levels is shown (top). Quantification of three independent experiments is shown as a percent increase in pY361 over Ctrl stimulation (bottom).
Error bars indicate ± SEM; *p < 0.05.
(E) Dissociated rat hippocampal neurons were transfected with GFP (gray) and stimulated as in panel (A), followed by fixing and staining for endogenous phos-
phorylated E5 using a-pY361 (Red). Representative image shown (left). White rectangle outlines magnified dendritic region showing examples of phospho-E5
staining (left bottom). Four independent experiments were imaged and analyzed for pY361 (bar graph). Error bars indicate ± SEM; *p < 0.05.
(F) Lysates from 293 cells transfected with empty vector (-) or increasing concentrations of E5-Myc with or without Flag-EphB2 were assessed for endogenous
RhoA activity by RBD assay (previously described). GTPgS lane is a positive control for inducing RhoA. Input protein levels and a-Actin loading control are shown
(bottom).
(G) WT and EphB2/ (B2/) brain lysates were immunoblotted with a-EphB2, a-N-E5, a-Actin, or a-pY361 according to methods (left). Quantification of a-N-E5
or a-pY361 signal from three independent experiments is normalized to a-Actin and represented as fold change compared to wild-type. Error bars indicate ±
SEM; *p < 0.05.
See also Figure S5.
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Figure 6. EphB2-Mediated Degradation of Ephexin5 Is Kinase- and
Proteasome Dependent
(A) Dissociatedmousehippocampal neuronswere incubatedwith preclustered
Fc, Fc-EB1 or Fc-EA1 for 60 min, lysed, and immunoprecipitated with a-C-E5
followed by immunoblotting with a-N-E5. Immunoblot of input with a-pEph or
a-Actin (loading control) are shown. Western is one representative image, and
quantification is of three separate experiments with samples normalized to
a-Actin (left). Error bars indicate ± SEM; *p < 0.05. Right, dissociated mouse
hippocampal neurons were transfected with GFP (gray) and stimulated with
either preclustered Fc (Ctrl) or Fc-EB1 (EB1) for 30 min, followed by fixing
and staining for endogenous E5 using a-N-E5 (red). White rectangle outlines
magnified dendritic region showing examples of E5 staining (right).
(B) Lysates from 293 cells previously transfected with various combinations of
overexpressingplasmids containing E5-Myc, E1-Myc and/or Flag-EphB2were
immunoblotted with a-Myc, a-Flag, or a-Actin (loading control).regulate synapse number. To determine if Ube3A and/or Cbl-b
catalyze E5 degradation we first asked if either of these E3
ligases interacts with and degrades E5 in 293 cells. When these
E3 ligases were epitope-tagged and expressed in 293 cells
together with E5 we found that E5 coimmunoprecipitates with
Ube3A but not with Cbl-b (Figure 7A). The coimmunoprecipita-
tion of Ube3A with E5 was specific in that Ube3A was not
coimmunoprecipitated with two other neuronal proteins, E1 or
the transcription factor MEF2. In a previous study we have
shown that Ube3A binds to substrates via a Ube3A binding
domain (hereafter referred to as UBD [Greer et al., 2010]). Using
protein sequence alignment programs, ClustalW and ModBase,
we identified a UBD in E5, providing further support for the idea
that E5 might be a substrate of Ube3A (Figure S7A). Consistent
with this hypothesis, we found that the level of E5 expression
is reduced in 293 cells cotransfected with titrating amounts of
Ube3A compared to cells cotransfected with titrating amounts
of Cbl-b (Figure S7B).
We asked if EB1/EphB-mediated E5 degradation in neurons is
catalyzed by Ube3A. To inhibit Ube3A activity we introduced into
neurons a dominant interfering form of Ube3A (dnUbe3A) that
contains a mutation in the ubiquitin ligase domain rendering
Ube3A inactive. We have previously shown that even though
dnUbe3A is catalytically inactive it still binds to E2 ligases and
to its substrates and functions in a dominant negative manner
to block the ability of wild-type Ube3A to ubiquitinate its
substrates (Greer et al., 2010). We found that when introduced
into 293 cells dnUbe3A binds to E5 (Figure 7A). We also found
by immunofluorescence microscopy that when overexpressed
in neurons, dnUbe3A blocks EB1/EphB stimulation of E5 degra-
dation (Figure 7B). EB1/EphB stimulation of E5 degradation was
also attenuated when Ube3A expression was knocked down by
a shRNA that specifically targets the Ube3A mRNA (Figure 7B;
Greer et al., 2010). Notably, the presence of the dnUbe3A did
not affect E5 expression in neurons in the absence of EphrinB
stimulation, suggesting that EphrinB stimulation of E5 Y361
phosphorylation may be required for Ube3A-mediated degrada-
tion of E5 (Figure S7C).
To determine if Ube3A-dependent degradation of E5 might be
relevant to the etiology of Angelman syndrome we asked if the
absence of Ube3A in a mouse model of Angelman syndrome
affects the level of E5 expression in the brain. We compared(C) Lysates from 293 cells previously transfected with various combinations of
overexpressing plasmids containing Flag-EphB2, Flag-EphB2KD and/or
E5-Myc were immunoblotted with a-Myc, a-Flag, or a-Actin (loading control).
(D) Lysates from 293 cells previously transfected with various combinations of
overexpressing plasmids containing E5-Myc, E5-Y361F-Myc and/or Flag-
EphB2 were immunoblotted with a-Myc, a-Flag, or a-Actin (loading control).
Representative immunoblot is shown (top). From three independent experi-
ments E5 levels were quantified and normalized to E5 expression in absence
of EphB2-Flag (bottom). Error bars indicate ± SEM; **p < 0.01.
(E) Dissociated mouse hippocampal neurons transfected with GFP (gray) were
stimulated similar to (B) in the absence or presence of lactacystin and immuno-
stained with a-N-E5. White rectangle outlines magnified dendritic region
showing examples of E5 staining (right).
(F) WT and E5/ brains were lysed and immunoprecipitated with a-C-E5
followed by immunoblotting with a-ub or a-N-E5.
See also Figure S6.
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Figure 7. EphB2-Mediated Degradation of
Ephexin5 Requires Ube3A
(A) Immunoprecipitation with a-HA from 293 cell
lysates previously transfected with various combi-
nations of plasmids containing E1-Myc, E5-Myc,
HA-DNUbe3A, HA-MEF2A, HA-Cbl-b, and/or HA-
Ube3A, followed by immunoblotting with a-HA or
a-Myc. Input protein levels and a-Actin loading
control are shown (bottom).
(B) Hippocampal mouse neurons were cotrans-
fected with GFP and control, HA-DNUbe3A or
Ube3A-shRNA at DIV10. At DIV14, neurons were
incubated with clustered Fc () or Fc-EB1 (+) for
30 min. Neurons were fixed and stained for E5
with a-N-E5 and quantified as described in the
methods. Quantification is of E5 staining intensity
normalized to Fc control. Error bars ± SEM; **p <
0.01, ANOVA.
(C) Ube3A wild-type and maternal-deficient
(Ube3Am-/p+) mouse brains were lysed and immu-
noblotted with a-N-E5, a-EphB2, a-MEF2, a-Actin
(loading control), or a-Ube3A (left). Samples were
normalized to a-Actin and quantified as described
in methods (right). Error bars indicate ± SEM; *p <
0.05, Mann-Whitney.
(D) Brain lysates from WT and Ube3Am-/p+ were
collected and treated similar to (C), immunoprecip-
itatedwith a-C-E5 and immunoblottedwith a-N-E5
and a-ub. Input protein levels are shown (right).
(E) Neurons from WT and Ube3Am-/p+ mice were
dissociated, cultured and transfected with GFP at
DIV10. At DIV14, neurons were incubated with pre-
clustered Fc or Fc-EB1 for 30 min. Neurons were
fixed and stained for E5with a-N-E5 and quantified
according to methods. Error bars indicate ± SEM;
**p < 0.01.
See also Figure S7.the level of E5 protein expression in the brains of wild-type mice
to that expressed in the brains of mice in which thematernally in-
herited Ube3A was disrupted (Ube3Am-/p+). Because the pater-
nally inherited copy of Ube3A is silenced in the brain due to
imprinting, the level of Ube3A expression in Ube3Am-/p+ neurons
is very low. We found that the level of E5 expression in the brains
of Ube3Am-/p+ mice was significantly higher than that detected in
the brains of wild-type mice (Figure 7C). Moreover, the level of
ubiquitinated E5 in brains of Ube3Am-/p+ mice was significantly
reduced compared to the brains of litter mate controls
(Figure 7D). In addition we found that when neurons from wild-452 Cell 143, 442–455, October 29, 2010 ª2010 Elsevier Inc.type and Ube3Am-/p+ brains were cultured
and then treated with EB1 the level of E5
protein was reduced upon EB1 treatment
in wild-type but not in Ube3Am-/p+
neurons (Figure 7E). Taken together,
these findings suggest that in response
to EB1 treatment E5 is tyrosine phosphor-
ylated by an EphB-dependent mecha-
nism, and that this leads to E5 degrada-
tion by a Ube3A-dependent mechanism.
If E5 degradation is disrupted due to
a loss of Ube3A as occurs in Angelmansyndrome the result is an increase in E5 expression and a disrup-
tion of the proper control of excitatory synapse number during
brain development.
DISCUSSION
Previous studies have revealed a role for EphrinB/EphB signaling
in the development of excitatory synapses (Klein, 2009).
However, the regulatory constraints that temper EphB-depen-
dent synapse development so that excitatory synapses form at
the right time and place, and in the correct number were not
known. In this study we identify a RhoAGEF, E5, which functions
to restrict EphB-dependent excitatory synapse development. E5
interacts with EphB prior to EphrinB binding, and by activating
RhoA serves to inhibit synapse development. The binding of
EphrinB to EphB as synapses form triggers the phosphorylation
and degradation of E5 by a Ube3A-dependent mechanism. The
reduction in E5 expression may allow EphB to promote excit-
atory synapse development by activating Rac and other proteins
at the synapse.
The findings that E5 functions to restrict excitatory synapse
number suggests that, even though EphBs promote excitatory
synapse development, there are constraints on the activity of
EphB so that synapse number is effectively controlled. There
are several steps in the process of synapse development where
E5 may function to restrict synapse number. One possibility is
that E5 functions early in development as a barrier to excitatory
synapse formation by activating RhoA and restricting the motility
or growth of dendritic filopodia that are the sites of contact by the
presynaptic neuron. For example, by inhibiting dendritic filopo-
dia formation or motility, E5 may decrease the number of
contacts the filopodia make with the presynaptic neuron, thus
resulting in the formation of fewer synapses. An alternative
possibility is that E5 functions to restrict synapse number later
in development perhaps to counterbalance the positive effects
of EphB on Rac that promote dendritic spine development. An
additional possibility is that E5 functions after excitatory synapse
development as a regulator of synapse elimination.
Our analyses of E5 function are most consistent with the
possibility that E5 functions early in the process of synapse
development. First, we find that E5 is expressed, active, and
bound to EphB prior to synapse formation. Second, the interac-
tion of EphrinBwith EphB, a process that is thought to be an early
step in excitatory synapse development, triggers the degrada-
tion of E5. Third, our preliminary time-lapse imaging studies
suggest that E5 is localized to newly formed filopodia prior to
synapse development where it appears to restrict filopodia
motility and growth (Margolis et al. unpublished). Thus, E5 might
function as an initial barrier to synapse formation until it is
degraded upon EphrinB binding to EphB.
It is possible that through its interaction with EphB, E5 marks
the sites where synapses will form, and that the degradation of
E5 is a critical early step in excitatory synapse development.
While the mechanisms by which E5 is degraded are not fully
understood, our studies suggest that the phosphorylation of
the N-terminus of E5 at Y361 triggers the Ube3A-mediated pro-
teasomal degradation of E5. One possibility is that prior to pY361
the N- and C-terminal portions of E5 interact, thereby protecting
E5 from degradation. The phosphorylation of E5 at Y361 may
relieve this inhibitory constraint allowing for E5 ubiquitination
and degradation. A similar mechanism has been shown to
regulate the activation of the Rac GEF Vav, (Aghazadeh et al.,
2000)). During EphrinA/EphA signaling it has been proposed
that Vav-mediated endocytosis of the EphrinA/EphA complex
may allow the conversion of the initial adhesive interaction
between EphrinA and EphA-expressing cells into a repulsive
interaction that results in growth cone collapse and axon repul-
sion. It is possible that E5 has a related function during EphB
signaling at synapses. Typically the EB/EphB interaction isthought to be repulsive. This has been documented in studies
of EphB’s role in the process of axon guidance (Egea and Klein,
2007; Flanagan and Vanderhaeghen, 1998). However, during
synapse development the EphrinB/EphB interaction is thought
to result in synapse formation, a process that requires an interac-
tion between the developing pre- and postsynaptic specializa-
tion. One possibility is that when EphrinB and EphB mediate
the interaction between the incoming axon and the developing
dendrite, the interaction is facilitated by the degradation of E5
by Ube3A. Since E5 is a RhoA GEF, its presence might initially
lead to repulsion between the incoming axon and the dendrite.
However, the EphB-dependent degradation of E5 might convert
this initial repulsive interaction into an attractive one.
The finding that Ube3A is the ubiquitin ligase that controls
EphB-mediated E5 degradation is of interest given the role of
Ube3A in human cognitive disorders such as Angelman syn-
drome and autism. The absence of Ube3A function in Angelman
syndrome would be predicted to result in an increase in E5
protein expression, and thus a decrease in EphB-dependent
synapse formation. Consistent with this possibility, we find in a
mousemodel for Angelman syndrome that the level of E5 protein
expression is elevated and that in response to EphrinB treatment
E5 is not degraded. Likewise, several studies have indicated that
synapse development and function is disrupted in these mice
(Jiang et al., 1998; Yashiro et al., 2009).
The recent finding that the Ube3A gene lies within a region of
chromosome 15 that is sometimes duplicated in autism raises
the possibility that altered levels of Ephexin5 and the resulting
defects in excitatory synapse restriction might also be a mecha-
nism relevant to the etiology of autism. If this is the case, a
possible therapy for treating autism might be to reduce the level
of Ube3A activity, and thus increase the level of Ephexin5 ex-
pression. It is important to consider that in addition to Ephexin5,
Ube3A regulates the abundance of other synaptic proteins.
Nevertheless, the ultimate effect of the aberrant expression of
Ephexin5 and other Ube3A substrates on synapse development
and function will require further study. It seems likely that such
studies will provide further understanding of the development
of human cognitive function and new insights into how this
process goes awry in disorders such as Angelman syndrome
and autism.
EXPERIMENTAL PROCEDURES
DNA Constructs
Details of DNA constructs can be found in Supplemental Information.
Generation of E5/ Mice
An E5 targeting vector was electroporated into 129 J1 ES cells, and positive
clones were identified by Southern hybridization with two separate probes
(see Supplemental Information).
Antibodies
Details of antibodies can be found in Supplemental Information.
Mice, Cell Culture, Transfections, and Ephrin Stimulations
Ube3Am/p+ mice were previously described (Greer et al., 2010). EphB2
knockout mice were previously described (Kayser et al., 2008). 293T cells
were cultured in DMEM + 10% FBS and transfected using the calcium phos-
phatemethod.Organotypic slice cultureswere prepared fromP6mousebrainsCell 143, 442–455, October 29, 2010 ª2010 Elsevier Inc. 453
and biolistically transfected. Acute slices were prepared from P12-14 mice.
Dissociated neurons were cultured in Neurobasal Medium supplemented
with B27 and transfected using the Lipofectamine method. For details on cell
culture, transfections, and Ephrin stimulations, see Supplemental Information.
Cell Lysis, Immunoprecipitations, GEF Pull-Down Assays,
and Western Blots
Whole rat ormouse brains or cultured cells were collected and homogenized in
RIPA buffer. For immunoprecipitations, lysed cells were centrifuged and
supernatants were incubated with appropriate antibody for 2 hr at 4C, fol-
lowed by addition of Protein-A or Protein-G beads (Santa Cruz Biotechnology)
for 1 hr, and washed three times with ice-cold RIPA buffer. For the a-PY361
detection experiment in 293T cells, samples were boiled in SDS buffer to
disrupt the E5/EphB2 interaction and diluted 1:5 in 1.253 RIPA buffer prior
to immunoprecipitation of E5-Myc. RBD and PBD pull-down assays were
conducted according to the manufacture’s suggestions (Upstate Cell
Signaling Solutions). For details see Supplemental Information.
In Situ Hybridization
To generate probes for in situ hybridization, mouse E5 and EphB2 cDNA were
subcloned into pBluescript II SK (+). Bluescript plasmids containing E5 or
EphB2 cDNA were linearized using the restriction enzyme BssHII. Sense and
antisense probes were generated using DIG RNA labelingmix (Roche) accord-
ing to manufacturer’s instructions. Full-length DIG-labeled probes were
subjected to alkaline hydrolysis as described in Supplemental Information.
Immunocytochemistry
Neurons were paraformaldehyde fixed in PBS. For measuring synapse
density, fixed neurons were incubated with a-PSD-95 and a-Synapsin
antibodies followed by a-Cy3 and a-Cy5 antibodies to visualize the primary
antibodies. For protein colocalization experiments fixed neurons were similarly
treated using a-EphB2 antibodies and a-N-E5 antibodies or a-pY361-E5.
For overexpression studies fixed neurons were incubated using a-Myc or
a-Flag antibodies to visualize overexpressed E5-Myc or EphB2-Flag protein
in the context of the GFP-labeled neurons. For details see Supplemental
Information.
Synapse Assay, Image Analysis, and Quantification
Imageswere acquired on a Zeiss LSM5Pascal confocal microscope and spine
and synapse analysis was performed as previously described (see Supple-
mental Information).
Ube3Am/p+ Cultures
Dissociated hippocampal neurons from Ube3Am/p+ and wild-type mice were
prepared as previously described (Greer et al., 2010).
Array Tomography
Array tomography was performed as previously described (Micheva and
Smith, 2007) with modifications as described in the Supplemental Information.
Electrophysiology
Electrophysiology was performed using standard methods (see Supplemental
Information).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at doi:10.1016/j.cell.
2010.09.038.
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